Stock Analysis
Insmed, Inc.INSM
Sector: Healthcare · Industry: Pharmaceutical Preparations
AnalystsStrong Buy30 analystsPrice is 4% of the way from the year's low to its high.
Cash covers 345% of debt · Q2 2025.
PMP Verdict
Weak fundamentals, expensive
Strengths
- Financial Health68
Risks
- Valuation25
- Growth0
Weak fundamentals at a demanding price.
Market context
-3.0% today· Z 0.9σ
What's happening with INSM
Profile
growth, profitability, earnings quality, valuation and moat lag behind.
How is each axis scored?
- Valuation25/100 · Weak
- P/E vs own history (n/a)10/25
- FCF yield (-3.8%)0/25
- P/S (19.0x)5/25
- EV/EBIT (n/a)10/25
- Growth0/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (n/a)0/25
- Profitability0/100 · Weak
- ROIC (n/a)0/25
- ROE (-118.4%)0/25
- Net margin (-76.9%)0/25
- Operating margin (-73.9%)0/25
- Financial Health68/100 · Moderate
- Altman Z (2.94)18/25
- Current ratio (3.83)25/25
- Interest coverage (-6.9x)0/25
- Net cash / debt (Net cash)25/25
- Quality5/100 · Weak
- Piotroski F (2/9)5/25
- Beneish M (n/a)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 552.0%)0/25
- Moat25/100 · Weak
- ROIC >12% years (0/8 yrs)0/25
- Median gross margin (76.6%)25/25
- FCF-positive years (0/10 yrs)0/25
- Worst-year net margin (worst -3297.2%)0/25
Risk Flags
- ⚠10 loss-making years in recent history
- ⚠Interest coverage -6.9× — thin debt cushion
About Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Show more
Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Headquarters: BRIDGEWATER, NJ · Employees: 1,664 · Website ↗
Price History
Weekly Candlestick Chart — up to 5Y
Key Metrics
Financial snapshot · Tap any metric for its definition and grade
TTM Snapshot
trailing twelve months · YoYValuation
25EP/E (TTM)—
Price / TTM EPS (own statements)
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield-3.8%D
Grade D: NegativeTTM (OCF − CapEx) / Market Cap — vs own 5Y history: -20.2%–-2.2% · 79th pct
P/S (TTM)18.96xD
Grade D: ExpensivePrice / TTM Revenue (own statements) — vs own 5Y history: 8.3x–177.4x · 83rd pct
EV/EBITDA—
Enterprise value / EBITDA (Finnhub) — capital-structure neutral
EV/Sales19.1xD
Grade D: Very expensiveEnterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E647.6xD
Grade D: ExpensivePrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio28.44xD
Grade D: Very expensivePrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio—
Finnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
0EROIC—
NOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE-118.4%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA-39.8%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin-76.9%D
Grade D: LowNet Income / Revenue
Operating Margin—
TTM EBIT / TTM Revenue
Gross Margin83.5%A
Grade A: PremiumGross Profit / Revenue
FCF Margin—
FCF / Revenue
True FCF Margin—
TTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Growth
0ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Implied EPS Growth—
Analyst forward EPS (normalized basis) vs our GAAP TTM EPS — different bases, so extreme values usually mark cyclically depressed TTM earnings, not real growth
Dilution (5Y)+105.4%D
Grade D: DilutiveShare count change over 5Y
SBC / Net Income—
Stock-based comp/Net income. >30% = dilution risk
SBC / Revenue—
TTM stock-based comp / TTM Revenue
Financial Health
68BAltman Z-Score2.94C
Grade C: Gray zoneBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio3.83xA
Grade A: HighCurrent Assets/Liabilities
Quick Ratio3.14xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage-6.9xD
Grade D: RiskyEBIT/Interest. >10 Strong
Debt RepaymentNet CashA
Grade A: FastYears to repay net debt via FCF
Net Debt/EBIT1.1xA
Grade A: LowLeverage. <2x Low, >4x High
Debt/Equity0.73xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt2.64xA
Grade A: CoveredCash covers how much of total debt. >1 = could repay all debt from cash
Quality
5EPiotroski F-Score2/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability552.0%D
Grade D: VolatileEBIT margin std deviation. Lower = stable
Capex / Revenue—
TTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.52xC
Grade C: AverageRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Insider Transactions
SEC Form 4 · 8 recordsP/S codes are the directional signal; grants, option exercises and tax withholding carry none. Form 4 doesn't flag 10b5-1 plans — scheduled sales may appear within open-market sells.
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Brennan David R Filed | Brennan David R | SellOpen market sale | -25000 | |
SHAROKY MELVIN MD Filed | SHAROKY MELVIN MD | SellOpen market sale | -5000 | |
Adsett Roger Filed | Adsett Roger | Option exercise | -80970 | |
Adsett Roger Filed | Adsett Roger | Option exercise | -76600 | |
Adsett Roger Filed | Adsett Roger | Option exercise | -82280 |
Show 3 more filingsShow fewer filings
| Trade date | Insider | Transaction | Shares | Filed |
|---|---|---|---|---|
Adsett Roger Filed | Adsett Roger | SellOpen market sale | -239850 | |
Adsett Roger Filed | Adsett Roger | Option exercise | +81.0K | |
Adsett Roger Filed | Adsett Roger | Option exercise | +76.6K |
Option exercise (M) rows report a derivative leg, not an open-market sale — a paired negative entry is the option position being consumed.
More metrics — Moat, Per Share, Balance Sheet, MarketHide additional metrics
Moat
25EROIC >12% Years0/8 yrsD
Grade D: WeakShare of completed fiscal years with ROIC > 12% — measures multi-year capital-return durability
Gross Margin (Med.)76.6%A
Grade A: DurableMedian annual gross margin across available fiscal years — pricing-power durability
FCF-Positive Years0/10 yrsD
Grade D: WeakShare of completed fiscal years with positive free cash flow
Net Margin Floor-3297.2%D
Grade D: WeakWeakest annual net margin across completed fiscal years — recession/downcycle resilience
Per Share
EPS (TTM)—
TTM net income per share (Finnhub fallback)
Cash / Share$5.32
Cash & short-term investments per share (Finnhub)
Book Value / Share$3.47
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$540.96M
Total debt obligations (short + long term)
Cash & Equiv.$1.43B
Cash and short-term investments
Net Debt$-889.04MA
Grade A: Net CashTotal Debt minus Cash. Negative = Net Cash position
Total Equity$738.98M
Shareholders' equity (book value)
Asset / Liability1.48xC
Grade C: AdequateTotal Assets / Total Liabilities
Market
Market Cap$21.02B
Current Market Capitalization
Beta0.82B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Jun 2026 · Ratio snapshot Oct 17, 2026
Key Insights: Insmed, Inc. (INSM)
INSM is down 2.96% at the last close. Insmed, Inc. meets only 2 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 2.94 falls in the grey zone (1.81–2.99) — financial distress is unlikely but not ruled out. Company is effectively debt-free after netting cash.
- Interest coverage of -6.9× leaves little room for earnings shocks.
- Insmed, Inc. posted a net loss in 10 of 10 available completed fiscal years (2016–2025).
- At a valuation score of 25/100, INSM trades at a premium to its historical multiples.
See how INSM ranks on the Capex Tracker — top 50 capital spenders compared.
Recent Market Moves
See all INSM moves →| Date | Session | Price | Move | Z-Score |
|---|---|---|---|---|
| Oct 5 | Regular | 104.38 | -6.07% | -2.36 |
| Oct 5 | After-hours | 104.83 | -5.66% | -2.18 |
Frequently Asked Questions about INSM
What is the current Insmed, Inc. (INSM) stock price?
INSM is trading at $96.27 at the last market close, down 2.96% on the session. PreMarketPrice tracks INSM pre-market, intraday and after-hours prices.
Is INSM stock a buy right now?
PreMarketPrice's quantitative model rates Insmed, Inc.'s financial health at 68/100. This is a data-driven snapshot of fundamentals, not investment advice.
Is INSM stock overvalued?
Insmed, Inc. trades at a trailing P/E of n/a and our valuation score rates it 25/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Insmed, Inc. report earnings?
No confirmed earnings date is currently scheduled for INSM. The Earnings section lists recent reports and updates as dates are announced.
What sector does Insmed, Inc. operate in?
Insmed, Inc. operates in the Healthcare sector, within the Pharmaceutical Preparations industry. The Related Stocks section lists sector peers for comparison.
What does Insmed, Inc. do?
Insmed Inc is a biopharmaceutical company.
About Insmed, Inc. (INSM) Stock
Insmed, Inc. (INSM) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry. As of the latest update, Insmed, Inc. is trading at $96.27, down 2.96% on the day with a market capitalization of $21.0 billion. The financial health score for INSM is 68/100, which indicates good financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for INSM stock.
INSM Stock Analysis & Key Metrics
On PreMarketPrice, you can track Insmed, Inc. (INSM) across multiple dimensions:
- Pre-market price & movement: Real-time INSM stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for INSM with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Insmed, Inc. across multiple reporting periods.
- Financial health score: A composite score of 68/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for INSM.
- Sector peers: Compare INSM against 6 other healthcare stocks on key financial metrics.
Is INSM a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Insmed, Inc. (INSM) as an investment. The financial health score of 68/100 suggests good financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Insmed, Inc. (INSM) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.